Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...
Actinium Pharmaceuticals (NYSE:ATNM) Earns “Buy” Rating from HC Wainwright
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...
Telix’s new lead-212 generator could dispel medical isotope scalability hurdles
Australia-based radiopharmaceutical company Telix Pharmaceuticals has created a new radionuclide generator that could ...
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a ...
Actinium Pharmaceuticals initiates Actimab-A Triplet combination frontline trial
Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...
Targeted Oncology17h
Actimab-A Triplet Trial Launches in Frontline AML
The first clinical trial under the Cooperative Research and Development Agreement with the National Cancer Institute and ...
Investing2d
Actinium launches new AML treatment trial with NCI
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration ...
Morningstar2d
Cellectar Biosciences to Present at the 37th Annual Roth Conference
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program ...
manilatimes2d
Cellectar Biosciences to Present at the 37th Annual Roth Conference
The company's product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being ...
pharmaphorum1d
AZ agrees $2bn deal to buy radiopharma firm Fusion
Fusion’s take on the technology is the use of actinium-225-based alpha particle emitters that can be attached to antibodies as well as other carriers like peptides and small-molecule drugs.
Neuroendocrine Tumors Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Neuroendocrine tumors Pipeline Insight” report provides comprehensive insights about 100+ companies and 120+ ...
Investing1d
Actinium launches new AML treatment trial with NCI
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration with ...